Trade-offs in prenatal detection of down syndrome

American Journal of Public Health

Volumn 88, Issue 4, 1998, Pages 551-557

  Serra Prat, Mateu ^a   Gallo, Pedro ^a   Jovell, Albert J ^a   Aymerich, Marta ^a   Dolors Estrada, M ^a  

^a Catalan Agency for Health Technology Assessment and Research   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; ESTRADIOL;

AMNIOCENTESIS; ARTICLE; DIAGNOSTIC ACCURACY; DOWN SYNDROME; ECHOGRAPHY; FEMALE; FETUS WASTAGE; HEALTH CARE POLICY; HUMAN; INTERMETHOD COMPARISON; OUTCOMES RESEARCH; PRENATAL DIAGNOSIS; PRENATAL SCREENING; SPAIN;

EID: 0031853194     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.88.4.551     Document Type: Article

References (35)

1. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol. 1987;94:387-402.
2. Wald NJ, Cuckle HS, Densem JW, et al. Maternal screening for Down's syndrome in early pregnancy. BMJ. 1988;297:883-887.
3. Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler I. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ. 1992;305:391-394.
4. Spencer K, Coombes EJ, Mallard A, Ward AM. Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem. 1992;29:506-518.
5. MacDonald ML, Wagner RM, Slotnick RN. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol and maternal age. Obstet Gynecol. 1991;77:63-68.
6. Phillips OP, Elias S, Shulman LP, Andersen RN, Morgan CD, Simpson JL. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG and unconjugated oestriol: a prospective 2-year study. Obstet Gynecol. 1992;80:353-358.
7. Haddow JE, Palomaki GE, Knight GJ, et al. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992;327:588-593.
8. Benacerraf BR, Gelman R, Frigoletto FD. Sonographic identification of second-trimester fetuses with Down's syndrome. N Engl J Med. 1987;317:1371-1376.
9. Lockwood C, Benacerraf B, Krinsky A, et al. A sonographic screening method for Down syndrome. Am J Obstet Gynecol. 1987;157: 803-808.
10. Vintzileos AM, Egan FX. Adjusting the risk for trisomy 21 on the basis of second trimester ultrasonography. Am J Obstet Gynecol. 1995;172:837-844.
11. Tabor A, Philip J, Madsen M, Bang J, Obel EB, Norgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986;i:1287-1293.
12. Meade TW, Ammälä P, Aynsley-Green A, et al. Medical Research Council European Trial of chorion villus sampling. Lancet. 1991;337: 1491-1499.
13. Weinstein MC, Fineberg HV, Elstein AS, et al. Clinical Decision Analysis. Philadelphia, Pa: WB Saunders Co; 1980.
14. Sonnenberg FA, Hagerty CG, Kulinowski CA. An architecture for knowledge-based construction of decision models. Med Decis Making. 1994;14(1):27-39.
15. Fletcher J, Hicks NR, Kay JDS, Boyd PA. Using decision analysis to compare policies for antenatal screening for Down's syndrome. BMJ. 1995;311:351-356.
16. Goodbum SF, Yates JRW, Raggart PR, et al. Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: experience of a regional programme. Prenat Diagn. 1994;14:391-402.
17. Cheng EY, Luthy DA, Zebelman AM, Williams MA, Lieppman RE, Hickok DE. A prospective evaluation of a second-trimester screening test for Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol. 1993;81:72-77.
18. Burton BK, Prins GS, Verp MS. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Am J Obstet Gynecol. 1993;169:526-530.
19. Haddow JE, Palomaki GE, Knight GJ, Cunningham GC, Lustig LS, Boyd PA. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med. 1994;330:1114-1118.
20. Mancini G, Perona M, Dall'Amico D, et al. Maternal serum markers. Estimation of the risk of Down's syndrome: a prospective study. Int J Clin Lab Res. 1994;24:49-53.
21. Perrella R, Duerinckx AJ, Grant EG, Tessler F, Tabsh K, Crandall BF. Second-trimester sonographic diagnosis of Down syndrome: role of femur-length shortening and nuchal-fold thickening. Am J Roentgenol. 1988;151: 981-985.
22. Lynch L, Berkowitz GS, Chitkara U, Wilkins IA, Mehalek KE, Berkowitz RL. Ultrasound detection of Down syndrome: is it really possible? Obstet Gynecol. 1989;73:267-270.
23. Ginsberg N, Cadkin A, Pergament E, Verlinsky Y. Ultrasonographic detection of the second-trimester fetus with trisomy 18 and trisomy 21. Am J Obstet Gynecol. 1990;63:1186-1190.
24. Crane J, Gray DL. Sonographically measured nuchal skinfold thickness as screening tool for Down syndrome: result of prospective clinical trial. Obstet Gynecol. 1991;77:533-539.
25. Donnenfeld AE, Carlson DE, Palomaki GE, Libruzzi RJ, Weiner S, Platt LD. Prospective multicentre study of second-trimester nuchal skinfold thickness in unaffected and Down syndrome pregnancies. Obstet Gynecol. 1994;84:844-884.
26. Gray DL, Crane JP. Optimal nuchal skin-fold thresholds based on gestational age for prenatal detection of Down syndrome. Am J Obstet Gynecol. 1994;171:1282-1286.
27. Borrell A, Martínez JM, Delgado RD, et al. Validez del pliegue nucal fetal como marcador ecográfico del sindrome de Down. Gac San. 1995;50(9):61.
28. Grandjean H, Sarramon MF, Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant Study Group. Sonographic measurement of nuchal skinfold thickness for detection of Down syndrome in the second-trimester fetus: a multicentre prospective study. Obstet Gynecol. 1995;85: 103-105.
29. Movimiento Natural de la Población Española 1992. Tomo II. Resultados por Comunidades Autónomas. Madrid, España: Instituto Nacional de Estadística: Cataluna. 1995.
30. Wishart JG. Prenatal screening for Down's syndrome. BMJ. 1991;303:468-469.
31. Murray D, Tennison B. Decision analysis and screening for Down's syndrome. Estimate of uptake of amniocentesis is overoptimistic. BMJ. 1995;311:1371.
32. Spencer K, Carpenter P. Risk of Down's syndrome and amniocentesis rate. BMJ. 1992; 304:640.
33. Halliday J, Lumley J, Watson L. Comparison of women who do and do not have amniocentesis or chorionic villus sampling. Lancet. 1995;345:704-709.
34. Shackley P, McGuire A, Boyd PA, et al. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome. J Public Health Med. 1993;15(2):175-184.
35. Registre d'interrupcions voluntàries de l'embaràs, avortament legal a Catalunya, 1992. Barcelona, Spain: Unitat d'Estadistiques Sanitàries, Direcció General de Recursos Sanitaris, Departament de Sanitat i Seguretat Social, Generalitat de Catalunya; 1993.